Senti Biosciences is trading 7.93% up at $0.37 after disclosing a newly authorized $2 million third tranche of senior secured convertible notes.
- The financing announcement followed a 6% after-hours gain and appears to be the primary catalyst.
- The company also disclosed Nasdaq-related notices and financing conditions.
- Its official investor-relations page identifies Senti Bio as a clinical-stage biotechnology company.